PMID- 22839725
OWN - NLM
STAT- MEDLINE
DCOM- 20130117
LR  - 20211021
IS  - 1756-0500 (Electronic)
IS  - 1756-0500 (Linking)
VI  - 5
DP  - 2012 Jul 27
TI  - Characterisation of a natural variant of the gamma-butyrolactone signalling receptor.
PG  - 379
LID - 10.1186/1756-0500-5-379 [doi]
AB  - BACKGROUND: The control of antibiotic production in Streptomyces coelicolor A3(2) 
      involves complicated regulatory networks with multiple regulators controlling the 
      expression of antibiotic biosynthetic pathways. One such regulatory network is 
      that of the gamma-butyrolactones, the so-called S. coelicolor butanolide (SCB) 
      system. The gamma-butyrolactones in this system serve as signalling molecules and 
      bind to the receptor protein ScbR, releasing the repression of its target genes. 
      The resulting expression changes affect the production of the two pigmented 
      antibiotics Act and Red, as well as the transcription of the cpk antibiotic 
      biosynthesis gene cluster and the synthesis of the gamma-butyrolactones themselves. 
      RESULTS: We identified a natural variant of ScbR in S. coelicolor (ScbRM600) that 
      differs from ScbR in the genome-sequenced strain M145 (ScbRM145) by a single 
      amino acid change, R120S. ScbRM600 is impaired in its DNA binding ability and 
      alters the expression of the pathway-specific regulatory genes of the red and cpk 
      antibiotic biosynthesis gene clusters. Also, expression of the gamma-butyrolactone 
      biosynthesis gene scbA and production of the signalling molecules is slightly 
      reduced. CONCLUSIONS: The gamma-butyrolactone receptor, ScbR, plays a key role in the 
      SCB regulatory cascade and in determining the onset of the expression of the 
      antibiotic regulatory genes.
FAU - Gottelt, Marco
AU  - Gottelt M
AD  - Department of Microbial Physiology, Groningen Biomolecular Sciences and 
      Biotechnology Institute, University of Groningen, Nijenborgh 7, 9747 AG, 
      Groningen, The Netherlands.
FAU - Hesketh, Andrew
AU  - Hesketh A
FAU - Bunet, Robert
AU  - Bunet R
FAU - Puri, Pranav
AU  - Puri P
FAU - Takano, Eriko
AU  - Takano E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120727
PL  - England
TA  - BMC Res Notes
JT  - BMC research notes
JID - 101462768
RN  - 0 (4-butyrolactone receptor)
RN  - 0 (Amino Acids)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Bacterial Proteins)
RN  - 0 (DNA, Bacterial)
RN  - 0 (Receptors, GABA-A)
RN  - 59-01-8 (Kanamycin)
RN  - EC 3.4.21.1 (Chymotrypsin)
SB  - IM
MH  - Amino Acid Sequence
MH  - Amino Acids/genetics
MH  - Anti-Bacterial Agents/biosynthesis
MH  - Bacterial Proteins/chemistry/*genetics/metabolism
MH  - Base Sequence
MH  - Chymotrypsin/metabolism
MH  - DNA, Bacterial/metabolism
MH  - Electrophoresis, Gel, Two-Dimensional
MH  - Electrophoretic Mobility Shift Assay
MH  - Escherichia coli/metabolism
MH  - Gene Expression Regulation, Bacterial/drug effects
MH  - Kanamycin/pharmacology
MH  - Molecular Sequence Data
MH  - Mutation/*genetics
MH  - Point Mutation/genetics
MH  - Promoter Regions, Genetic/genetics
MH  - Protein Binding/drug effects
MH  - Protein Structure, Tertiary
MH  - Receptors, GABA-A/chemistry/*genetics/*metabolism
MH  - Reproducibility of Results
MH  - Sequence Alignment
MH  - *Signal Transduction/drug effects
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
MH  - Streptomyces coelicolor/drug effects/*genetics/growth & development/*metabolism
MH  - Transcription, Genetic/drug effects
PMC - PMC3461410
EDAT- 2012/07/31 06:00
MHDA- 2013/01/18 06:00
PMCR- 2012/07/27
CRDT- 2012/07/31 06:00
PHST- 2012/02/24 00:00 [received]
PHST- 2012/07/27 00:00 [accepted]
PHST- 2012/07/31 06:00 [entrez]
PHST- 2012/07/31 06:00 [pubmed]
PHST- 2013/01/18 06:00 [medline]
PHST- 2012/07/27 00:00 [pmc-release]
AID - 1756-0500-5-379 [pii]
AID - 10.1186/1756-0500-5-379 [doi]
PST - epublish
SO  - BMC Res Notes. 2012 Jul 27;5:379. doi: 10.1186/1756-0500-5-379.